Skip to content
MARKETS / BALCAO / PURE
BALCAO · MISCELLANEOUS CHEMICAL PRODUCTS · SMALL CAP

Pure Bioscience, Inc. PURE

15 fiscal years on record · USD · FY2025 reported · SEC filings only
$2.2M
▲ 12.2% YoY
$-2.4M
In brief

What this company does

Our technology platform is based on patented stabilized ionic silver, and our initial products contain Silver Dihydrogen Citrate, or SDC. Our SDC-based disinfecting and sanitizing products are registered with the United States Environmental Protection Agency, or EPA, the United States Food and Drug Administration, or FDA, and Health Canada. In addition to manufacturing and distributing these products, we also supply SDC-based formulations as raw material ingredients for personal care products. Our registered offerings include PURE® Hard Surface, a food contact surface sanitizer and disinfectant designed for restaurant chains, food processors, and transportation companies, as well as PURE Control®, a direct food contact processing aid.

Written from the business description in PURE Bioscience, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 29 October 2025. Every sentence was checked against that document before publication.

Growth
USD 2.2M
Revenue, FY2025 · full 15-year series below
Revenue $M Net income $M
FY2025 · Revenue 2.2 · Net income -2.4
2.5M5.0M-5.0M-10.0M20112013201520172019202120232025
Compound annual growth
+5.9%
−20.5%
+11.7%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at −20.5% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−109 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -103.2% · Net -108.9%
-1000%-2000%20112013201520172019202120232025
ROE
FY2023 · ROE -189.5%
-200%-400%-600%20112013201520172019202120232025

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2023 · FCF -3.3
-2.5M-5.0M20112013201520172019202120232025

Total assetsUSD 1.1M
EquityUSD -5.1M
CashUSD 334,000.00
Gross debtUSD 5.2M
Net debtUSD 4.9M
Current ratio1.12×

Equity was negative — liabilities exceeded assets. No ratio is shown.

The 15-year record
15 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 202520242023202220212020201920182017201620152014201320122011
Revenue $B0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0
Operating income $B−0.0−0.0−0.0−0.0−0.00.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EBITDA $B−0.0−0.0−0.0−0.0−0.00.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Income tax $B0.00.00.00.00.00.00.00.00.00.00.0····
Net income $B−0.0−0.0−0.0−0.0−0.00.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B··−0.0−0.0−0.00.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EPS, diluted $−0.02−0.03−0.04−0.04−0.030.00−0.09−0.11−0.10−0.25−0.19−0.43−0.71−1.58−1.79
Dividend / sh $···············
Payout %···············
ROE %··−189.5−96.4−56.90.1−530.5−578.9−198.4−388.1−635.6··−353.8−198.5
Shares out B0.110.110.110.110.090.090.080.070.060.060.040.030.010.01·

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 66 reconciliationsAUDITED

Reconciled in 15 of 19 fiscal years. 21 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityMiscellaneous Chemical Products
Listed onOTC market
Incorporated inDelaware
Fiscal year endsJuly 31
SEC categorysmaller reporting company
Data on record since2011

Share this section

Download image